AI early diagnosis could save heart and cancer patients
AI early diagnosis could save heart and cancer patients By Pallab GhoshScience correspondent, BBC News2 January 2018 Original Article: http://www.bbc.com/news/health-42357257 Researchers at an Oxford hospital have developed artificial intelligence (AI) that can diagnose scans for heart disease and lung cancer. The systems will save billions of pounds by enabling the diseases to be picked up much earlier. The heart disease […]
Further Progress in BIOMARK’s Clinical Trial and Regulatory Review
Vancouver, British Columbia – (January 3rd, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide further progress on its clinical trial activities as previously reported on November 1st, 2017. New accomplishments over the past few weeks are listed below. Samples from the outlier cohort have been received at […]
Global Affairs Canada Supports BioMark’s Trip to Japan
Vancouver, British Columbia – (December 19th, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is proud to announce that the Canadian Government’s established Going Global International (GGI) program has generously approved its second application to further engage with top tier Japanese institutions following its successful initial visit in June 2017. Based […]
Dr. Ian Smith Joins BioMark’s Board of Directors
Vancouver, British Columbia – (December 5th, 2017)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Dr. Ian Smith has been elected to become a board director of the company. Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Smith to our board. His achievements in […]
BIOMARK’s Clinical Trial & Research Update
Vancouver, British Columbia – (November 1, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide the latest clinical trial update. The company analyzed samples from the clinical trials samples at a Good Laboratory Practice (GLP) facility, which utilized the Company’s internal standards (obtained under Health Canada’s Investigational Testing […]
BIOMARK ANNOUNCES PATENT GRANTED IN CHINA
Vancouver, British Columbia – (October 25th, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRASFERASE” has been prosecuted to allowance and issued in China. Rashid Ahmed, President and CEO, says, “Granting of this patent expands […]
BIOMARK ANNOUNCES APPOINTMENT OF SCIENTIFIC AND MEDICAL ADVISORS
Vancouver, British Columbia – (October 2nd, 2017)– BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed four distinguished experts to its scientific and medical advisory team. Announcements related to each adviser will be made through appropriate news release. Over the past few months our new advisors […]
BIOMARK ANNOUNCES MULTIPLE PATENTS ISSUED
Press_Release_BIOMARK_ANNOUNCES_MULTIPLE_PATENTS_ISSUED_ (PDF)
BIOMARK Closes First Tranche of Over-Subscribed Private Placement Offering
Press Release – Biomark Closes First Tranche of Private Placement Offering (PDF)
BIOMARK Appoints Ms. Guoyu Huang As Interim CFO
Press Release – BIOMARK APPIONTS MS GUOYU HUANG AS INTERIM CFO (PDF)